Patents by Inventor William Henry Miller

William Henry Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150307480
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 29, 2015
    Inventors: Steven David KNIGHT, William Henry MILLER, Kenneth Allen NEWLANDER, Carla A. DONATELLI
  • Patent number: 9114141
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 25, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: William Henry Miller, Xinrong Tian, Shared Kumar Verma
  • Publication number: 20150212654
    Abstract: Features are disclosed for proving a sequence of images scaled for substantially full screen presentation by browser applications executing on mobile computing devices. In some embodiments, a collection of story art images may be maintained. Each image may include a representation of a portion of a story, and the story may progress through the images in a predetermined sequence. A request from a mobile computing device for the next image in a sequence may be served with a copy of the next image in the sequence that has been scaled to the browser display area or the display size of the mobile device. Navigation features are disclosed for providing navigation operations without presentation of a visual indicator of the navigation operation.
    Type: Application
    Filed: January 28, 2014
    Publication date: July 30, 2015
    Applicant: Comikka, Inc.
    Inventor: William Henry Miller Beckett, JR.
  • Patent number: 9073924
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 7, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • Publication number: 20150152108
    Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: November 19, 2014
    Publication date: June 4, 2015
    Inventors: Charles A. BLUM, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee NG, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian White
  • Publication number: 20150141436
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: William Henry Miller, Xinrong Tian, Sharad Kumar Verma
  • Publication number: 20150126522
    Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 7, 2015
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Celine Duquenne, Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • Publication number: 20140343056
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: September 12, 2012
    Publication date: November 20, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • Patent number: 8765792
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 1, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • Publication number: 20130245016
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: November 30, 2011
    Publication date: September 19, 2013
    Inventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • Patent number: 7759340
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: July 20, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Patent number: 7709472
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: May 4, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Patent number: 7709496
    Abstract: 2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: May 4, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Alan T. Price
  • Patent number: 7691850
    Abstract: Compounds of formula (I) and derivatives thereof: compositions containing them, their preparation and their use as antibacterials.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: April 6, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Israil Pendrak, Mark Andrew Seefeld
  • Publication number: 20100081650
    Abstract: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Jeffrey Michael Axten, Robert A. Daines, David Thomas Davies, Timothy Francis Gallagher, Graham Elgin Jones, William Henry Miller, Neil David Pearson, Israil Pendrak
  • Patent number: 7655648
    Abstract: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: February 2, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Mark Andrew Seefeld
  • Patent number: 7648980
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: January 19, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Patent number: 7648984
    Abstract: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: January 19, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Jeffrey Michael Axten, Mark Andrew Seefeld
  • Patent number: 7622481
    Abstract: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: November 24, 2009
    Assignee: Glaxo Group Limited
    Inventors: Jeffrey Michael Axten, Robert A Daines, David Thomas Davies, Timothy Francis Gallagher, Graham Elgin Jones, William Henry Miller, Neil David Pearson, Israil Pendrak
  • Patent number: RE44613
    Abstract: The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: November 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, William Henry Miller, Andrea K. Myers, Antony N. Shaw, Michael N. Zimmerman